pharma · Vitiligo · Erythropoietic Protoporphyria (EPP)
CLINUVEL PHARMACEUTICALS
Clinuvel Europe Limited
Clinuvel Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Vitiligo, Erythropoietic Protoporphyria (EPP), Parkinson's Disease, Arterial Ischaemic Stroke (AIS). NovaPharmaNews li
Melbourne, AU HQ
2001 Founded
83 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2001
- Employees
- 83
- Programs
- 5
- Drugs
- 3
- Patents
- 0
SCENESSE 16 mg implant
Phase 2 · small molecule · Erythropoietic Protoporphyria (EPP)
SCENESSE 16 mg implant for Erythropoietic Protoporphyria (EPP) is a Phase 2 program (small_molecule) at Clinuvel Europe Limited with 1 ClinicalTrials.gov record(s).
Internal code CUV052
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Clinuvel Europe Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Erythropoietic Protoporphyria (EPP)
- Status
- active
- Trials
- 1